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Abstract
Background: Proposed neonatal quality measures have included structural measures such as average daily census,
and outcome measures such as mortality and rates of complications of prematurity. However, process measures
have remained largely unexamined. The objective of this research was to examine variation in surfactant use as a
possible process measure of neonatal quality.
Methods: We obtained data on infants 30 to 34 weeks gestation admitted with respiratory distress syndrome
(RDS) within 48 hours of birth to 16 hospitals participating in the Pediatric Health Information Systems database
from 2001-2006. Models were developed to describe hospital variation in surfactant use and identify patient and
hospital predictors of use. Another cohort of all infants admitted within 24 hours of birth was used to obtain
adjusted neonatal intensive care unit (NICU) mortality rates. To assess the construct validity of surfactant use as a
quality metric, adjusted hospital rates of mortality and surfactant use were compared using Kendall’s tau.
Results: Of 3,633 infants, 46% received surfactant. For individual hospitals, the adjusted odds of surfactant use
varied from 2.2 times greater to 5.9 times less than the hospital with the median adjusted odds of surfactant use.
Increased annual admissions of extremely low birth weight infants to the NICU were associated with greater
surfactant use (OR 1.80, 95% CI 1.02-3.19). The correlation between adjusted hospital rates of surfactant use and
in-hospital mortality was 0.37 (Kendall’s tau p = 0.051).
Conclusions: Though results were encouraging, efforts to examine surfactant use in infants with RDS as a process
measure reflecting quality of care revealed significant challenges. Difficulties related to adequate measurement
including defining RDS using administrative data, accounting for care received prior to transfer, and adjusting for
severity of illness will need to be addressed to improve the utility of this measure.
Background
Measuring the quality of health care has become a major
focus of policymakers, health care purchasers, and physi-
cians. Traditionally, quality of care is measured by one of
three dimensions–structure (characteristics of the envir-
onment in which care is delivered), process (care itself or
what is actually done to a patient), or outcome (the
patient’s health status). Neonatal quality measures that
have been examined include structural measures such as
average daily census, and outcome measures such as
mortality and rates of complications of prematurity.
However, process measures of neonatal quality have
remained largely unexamined.
The best processes to use as quality indicators are
those linked to improved outcomes through sound scien-
tific evidence [1,2]. Surfactant therapy for neonatal
respiratory distress syndrome (RDS) serves as an excel-
lent evidence-based process measure. In both very low
birth weight (VLBW, <1500 grams) [3] and larger [4-6]
preterm infants, it has been shown to lead to a significant
decrease in the risk of mortality and pneumothorax [7,8].
Additionally, position statements from professional orga-
nizations support use of this proven therapy in infants of
any gestational age with RDS [9-11]. However, while
there is documented variation in the evidence-based use
of surfactant among VLBW infants [12,13], variation in
evidence-based surfactant use among larger preterm
infants–the most prevalent group of preterm infants–has
* Correspondence: heather.kaplan@cchmc.org
1Perinatal Institute and James M. Anderson Center for Health Systems
Excellence, Cincinnati Children’s Hospital Medical Center, 3333 Burnet
Avenue, Cincinnati, OH, USA
Full list of author information is available at the end of the article
Kaplan et al. BMC Health Services Research 2011, 11:22
http://www.biomedcentral.com/1472-6963/11/22
© 2011 Kaplan et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.not been examined. Additionally, given that a majority of
preterm infants are delivered moderately preterm and
these patients are not targeted by current quality mea-
sures, concerted efforts are needed to identify and vali-
date measures targeting this patient population [14].
The ideal approach to quality measurement incorpo-
rates structure, process, and outcome dimensions of
quality and utilizes indicators that are valid, reliable, and
easy to collect [15]. Rigorous development of potential
quality of care measures requires establishing that the
measure has (1) face validity–the perception that the
measure actually reflects better or worse care; (2) con-
struct validity–evidence that quality as measured by the
proposed metric is consistent with quality when mea-
sured by other metrics; and, (3) stability over time. It also
requires that the proposed metric be adequately mea-
sured with available data sources
We aimed to assess whether surfactant use in infants
30 to 34 weeks’ gestation with RDS is a valid measure of
neonatal intensive care unit quality of care. Face validity
was established by identifying support for this process in
the medical literature and recommendations from profes-
sional organizations [9-11]. The objective of this study was
to determine whether significant variation exists in the use
of surfactant among infants infants 30 to 34 weeks’ gesta-
tion across hospitals and to test the construct validity of
surfactant use as a quality measure by identifying charac-
teristics associated with higher rates of use and comparing
ratings with two measures of quality–volume of admis-
sions [16-18] and in-hospital mortality [16,17,19].
Methods
The protocol was reviewed by The Children’sH o s p i t a l
of Philadelphia Institutional Review Board (IRB) and
was determined to be IRB exempt.
Data source
Data were obtained from the Pediatric Health Informa-
tion Systems (PHIS) database developed by the Child
Health Corporation of America, a business alliance of
freestanding, children’s hospitals. PHIS contains data
from 40 not-for-profit, tertiary care United States chil-
dren’s hospitals. This database contains demographic
information, diagnosis and procedure codes (recorded
using the International Classification of Diseases, 9
th
Revision, Clinical Modification (ICD-9-CM) format) and
billed transaction and utilization data which are mapped
to standardized Clinical Transaction Classification
(CTC) codes. The database also contains all-patient
refined diagnosis-related groups (APR-DRGs, version
15) and their associated birth weight groupings, as
determined from patients’ diagnosis and procedure
codes and submitted birth weight (if available) using 3M
proprietary software.
Study population
The study cohort consisted of infants born at 30 to
34 weeks gestation with RDS, admitted between January 1,
2001 and March 31, 2006 to a hospital participating in the
PHIS database. We defined RDS as requiring respiratory
support with nasal continuous positive airway pressure
(NCPAP) or mechanical ventilation (MV) in the first
48 hours of life, as determined from billing CTC codes
and ICD-9-CM procedure codes. We chose to use a clini-
cal definition of RDS instead of the ICD-9-CM diagnosis
code (ICD-9-CM 769) in our primary analysis because
assignment of the ICD-9-CM code is done retrospectively
and may be biased by whether an infant received surfac-
tant. Additionally, the ICD-9-CM code for RDS has never
been specifically validated andi ti sl i k e l ys u s c e p t i b l et o
coding errors because it requires significant judgment
by data abstractors. We excluded infants admitted at
>48 hours of life, who wouldb eo u t s i d et h et r e a t m e n t
window for surfactant, and infants with congenital anoma-
lies. We included data only from hospitals that submitted
gestational age information. Hospitals that did not submit
gestational age were similar to hospitals that did with
regard to number of staffed beds, average daily census,
and population of the surrounding city. We also included
only those hospitals that submitted both billing and clini-
cal data to PHIS. Hospitals with <40 eligible infants in the
study period were excluded to minimize unstable esti-
mates of the outcome in small centers. Figure 1 describes
how the exclusion and inclusion criteria were applied to
obtain the final study population.
Data quality and missing data
PHIS data are warehoused by a third-party vendor (pre-
viously Solucient, Ann Arbor, MI) which loads and pro-
cesses data submitted by the hospitals. The warehouse
partner applies 175 audits to each patient record. Sub-
missions that do not meet the error thresholds are
rejected. For example, neonate specific audits include
identifying inconsistencies in typical length of stay
(LOS) for a given birth weight group (i.e. LOS < 45 days
for infant 600-749 grams) and identifying potential mis-
classifications of preterm and full term infants (i.e.
BW < 2500 grams for a full term infant and BW > 2500
grams for a preterm infant). The hospital must correct
the errors, resubmit the data, and meet the threshold
before the data is included in PHIS.
A majority of the variables had missing data in <5% of
observations. Race information was missing for 6% of
patients. Among the population used to measure
in-hospital mortality rates, 7.5% of patients had a gesta-
tional age that was determined to be inaccurate
(<22 weeks or >43 weeks) or was missing. Patients with
missing data were included in all analyses with variables
coded in the regression models as absent (reference),
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data were carried out for several aspects of the data
analysis using imputed data and the results did not vary
substantively from those presented here.
Outcome of interest
The primary outcome measure was receipt of surfactant
within the first 48 hours of life. Surfactant use was iden-
tified by presence of an appropriate CTC code for any
surfactant (i.e. lung surfactant unspecified, Beractant,
synthetic lung surfactant, Calfactant, and Poractant
alpha) in the pharmacy billing data. Only surfactant
charges with a day of service within the first 48 hours of
the infant’s life were included.
Hospital characteristics
Hospital identifying characteristics
Hospital factors of interest were the number of annual
extremely low birth weight (ELBW) admissions to the
NICU, percent Medicaid admissions to the hospital,
amount of National Institutes of Health (NIH) research
funding, and percent of admissions to the neonatal inten-
sive care unit (NICU) with a principal surgical diagnosis.
These variables were calculated for the most recent full
year in the database (2005). ELBW admissions were
defined using APR-DRG birth weight groupings. Amount
of NIH research funding was obtained from the National
Association of Children’s Hospitals and Related Institu-
tions for the year 2005.
Hospital measures used to test construct validity
The measure of volume of admissions used to test con-
struct validity was determined as described above. We also
aimed to test construct validity by comparing hospital
rates of surfactant use with overall in-hospital mortality
rates. This analysis is not intended to make a causal link
between surfactant use and mortality at the patient-level
but to examine whether rankings based on surfactant use
are similar to rankings based on overall in-hospital mortal-
ity rates at the hospital-level. Overall NICU rates of mor-
tality were determined using a second cohort of infants
from the same hospitals which consisted of 24,421 neo-
nates (any gestational age) admitted to a participating
PHIS NICU within 24 hours of birth during the same
study period. This second cohort was necessary to provide
the correct population for measuring overall in-hospital
NICU mortality as an outcome measure of quality. We
excluded five patients who lacked a recorded ICD-9-CM
procedure or diagnosis code. Physiologic measures of
severity of illness were unavailable in the PHIS database
and risk adjustment models have not specifically been vali-
dated for use with this database. Therefore, we used
demographic and clinical variables to control for differ-
ences in case-mix across hospitals when calculating
adjusted rates of surfactant use and mortality as in pre-
vious studies [16,20]. The variables available to control for
case-mix in our analyses (a subset of the variables included
in previous studies) included gender, presence of any con-
genital anomaly, race, gestational age, and birth weight
<10
th percentile for gestational age.
Statistical analysis
Analyses were carried out using Stata 9 (College Station,
TX); hypothesis tests were two-sided and used a Type I
error rate of 0.05. Odds ratios (OR) are presented with
their 95% confidence intervals (CI). Unless the model
included individual hospitals as fixed effects, we used
modified Huber-White sandwich estimators to adjust
the standard error estimates in the regression models
for possible correlations among patients from the same
hospital [21].
Variation in surfactant use and hospital characteristics
associated with use
We built a patient-level logistic regression model for the
study population that predicted surfactant use as a func-
tion of patient level variables (i.e. gestational age, race,
gender, day of life on admission, and mode of ventila-
tion). Indicator variables for specific hospitals were
added to the model to estimate odds of surfactant use
for each hospital relative to the hospital with the median
Figure 1 Inclusion and exclusion criteria applied to identify the
study population. This figure displays how inclusion and exclusion
criteria were applied to identify the study population. Prior to
obtaining data from PHIS, 11 hospitals that do not submit
gestational age information were excluded. From the initial study
population of infants 30 to 34 weeks gestation admitted in the first
48 hours of life, exclusion criteria were applied sequentially.
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patient characteristics.
Comparison with other quality measures–construct validity
We tested the construct validity of surfactant use as a
measure of quality by (1) examining the association
between surfactant use and hospital characteristics, spe-
cifically volume of admissions to the NICU (described
in previous section), and (2) comparing adjusted hospital
rates of surfactant use with adjusted hospital mortality
rates. For the first test, we examined the coefficient of
each hospital characteristic after individually adding the
hospital-level characteristic to the patient-level model.
For the second test of validity, using the population of
patients of all gestational ages admitted in the first
24 hours of life, we built a logistic regression model to
predict the odds of in-hospital mortality including cov-
ariates to adjust for case-mix (described in previous sec-
tion). Using the logistic regression model to estimate
the adjusted expected number of patient deaths (E) for
each hospital, we calculated an (O-E)/N statistic for
each hospital, where O was the observed number of
events (deaths) at a hospital and N was the number of
patients at the hospital [22]. We also calculated the
(O-E)/N statistics for surfactant use at each hospital
using the same methodology. This statistic reflects the
excess or reduction in rate of surfactant use (or mortal-
ity) of a given hospital compared to an “average” hospi-
tal with the same mixture of patient characteristics.
A test of whether the observed and expected rates dif-
fered was calculated using methods described by Haber-
man [23]. In addition, as a confirmatory analysis, we
used bootstrap techniques [24] to obtain a mean (O-E)/
N and 95% confidence interval for each hospital. The
association between adjusted hospital mortality rates
and adjusted hospital rates of surfactant use was
assessed using Kendall’s tau probability of concordance
(which is calculated by the formula 1+ tau)/2) and the
Kendall’s tau correlation coefficient [25]. The probability
of concordance provides the probability that if a hospital
is ranked higher on surfactant use, it will also have a
better (lower) adjusted mortality rate.
Sensitivity analyses
In order to test whether variation in the odds of surfac-
tant use among hospitals was robust to changes in the
definition of RDS, we performed a sensitivity analysis
defining RDS with the ICD-9-CM code for respiratory
distress syndrome (ICD-9-CM 769) as opposed to the
clinically derived definition of requiring ventilatory sup-
port (NCPAP or MV) in the first 48 hours of life. Addi-
tionally, to examine variationi nt h ep a t i e n tp o p u l a t i o n
specifically targeted by the American Academy of Pedia-
trics [10] for evidence based surfactant (intubated
infants with RDS) and to examine the possible effect of
receiving surfactant prior to transfer, we performed a
sensitivity analysis examining only the cohort of infants
admitted within 24 hours of birth who required
mechanical ventilation.
Results
Variation in rates of surfactant use
A total of 3,633 infants from 16 hospitals were included
in the study population. Mean gestational age was
32.2 ± 1.4 weeks. A majority of patients were male
(57.8%) and of white race (70.8%). Overall, 46% of these
patients received surfactant. Unadjusted rates of surfac-
tant use among hospitals ranged from 18.9% to 71.4%.
Among the 2,961 (81.5%) patients on mechanical venti-
lation during the first 48 hours of life, 55.6% received
surfactant. Seventy-eight percent had an ICD-9-CM
diagnosis code for RDS. Other diagnoses included con-
genital pneumonia (2.3%), meconium aspiration (0.2%),
transient tachypnea of the newborn (8.6%), and severe
birth asphyxia (0.7%). Of the included hospitals,
15 (94%) were academic centers and 14 (88%) were
located in a city with a population >1 million.
Multivariate models indicated that gestational age,
race, and gender were significantly associated with sur-
factant use (Table 1). Requiring mechanical ventilation
sometime during the first 48 hours of life, compared to
requiring only NCPAP, was most strongly associated
with receipt of surfactant (OR 55, 95% CI 36-84).
Receipt of surfactant was independent of whether the
infant was admitted in the first 24 hours of life (day 0)
or in the second 24 hours of life (day 1).
After adjusting for patient characteristics, five hospi-
tals had significantly decreased odds and four hospitals
had significantly increased odds of giving surfactant,
compared to the median hospital (Figure 2). Odds ratios
varied from as much as 2.2 (95% CI 1.53-3.23) times
greater to 5.9 (95% CI 2.72-12.3) times less than the
median hospital (p ≤ 0.001).
Among the 2,465 patients admitted within 24 hours of
birth who required mechanical ventilation, unadjusted
rates of surfactant use ranged from 19.2% to 76.3%
across hospitals. Additionally, significant variation in
adjusted surfactant use persisted in 7 of the 9 hospitals
that were significant in the original analysis (Hospitals
A, B, L, M, N, O, and P). Significant hospital variation
in surfactant use was also found when the cohort was
restricted to infants with an ICD-9-CM diagnosis code
for RDS.
Construct validity
Among hospital-level characteristics, patient volume was
significantly associated with variation in receipt of
surfactant, while involvement in research approached sig-
nificance (Table 1). NICU surgical volume and hospital
payer mix were not associated with surfactant use.
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with adjusted in-hospital mortality rates. The mean boot-
strap (O-E)/N values for surfactant use and death and the
Haberman p-values for each hospital are shown in Table
2. The association between hospital surfactant use (mea-
sured by the (O-E)/N statistic for surfactant) and in-hospi-
tal NICU mortality (measured by the (O-E)/N statistic for
death) is shown in Figure 3. The overall trend in the plot
was consistent with an association between decreasing
hospital mortality rates and increasing hospital rates of
surfactant use (Kendall’s tau correlation coefficient of 0.37,
implying a probability of concordance of 0.69, p = 0.051).
This plot shows one outlier hospital with very low mortal-
ity rates. As Kendall’s tau is rank-based and robust to out-
liers, the observed trend was unlikely to be driven by this
outlier. We also found a statistically significant correlation
between adjusted in-hospital NICU mortality rates and
adjusted hospital rates of surfactant use among
the population of infants requiring mechanical ventilation
(Kendall’s tau correlation coefficient of 0.38, also implying
a probability of concordance of 0.69, p = 0.047).
Discussion
Healthcare providers strive to provide high quality care
to their patients. However, in order to determine
whether we are actually providing outstanding care,
quality measures that are valid, reliable, and easy to col-
lect are needed. We attempted to demonstrate that sur-
factant use in infants 30 to 34 weeks gestation with RDS
may be a useful process measure of hospital quality.
Table 1 Predictors of surfactant use in cohort 1 (n = 3,633)*
Odds Ratio 95% CI p-value
PATIENT-LEVEL PREDICTORS*
Gestational age
30 weeks (n = 621) Reference
31 weeks (n = 620) 0.73 0.57-0.95 0.019
32 weeks (n = 747) 0.68 0.53-0.87 0.002
33 weeks (n = 715) 0.58 0.45-0.75 <0.001
34 weeks (n = 930) 0.69 0.55-0.88 0.003
Race†
Non-white (n = 840) Reference
White (n = 2,571) 1.22 1.02-1.47 0.03
Gender
Female (n = 1,535) Reference
Male (n = 2,098) 1.34 1.15-1.57 <0.001
Age at admission
Day of life 0 (n = 3,107) Reference
Day of life 1 (n = 526) 1.11 0.89-1.38 0.34
Mode of respiratory support (first 48 hrs)
NCPAP (n = 672) Reference
Mechanical ventilation (n = 2,961) 54.99 35.86-84.35 <0.001
HOSPITAL-LEVEL PREDICTORS††
Research involvement
Top 10 hospital based on NIH total awards to children’s hospitals 1.48 0.98-2.25 0.065
Surgical volume
≥ 29% (median) of admissions to the NICU classified as surgical 1.58 0.79-3.16 0.193
Payer mix
≥ 45% (median) of admissions to the hospital paid by Medicaid 0.80 0.40-1.61 0.532
Patient volume
≥ 45 (median) Annual ELBW Admissions 1.80 1.02-3.19 0.042
NCPAP = nasal continuous positive airway pressure, NIH = National Institutes of Health; NICU = neonatal intensive care unit; ELBW = extremely low birth weight.
*Model includes patient-level variables listed in the table plus hospital fixed effects.
†Model includes a term for missing race (n = 222).
††Model includes patient-level variables listed in the table plus hospital characteristics added individually.
Kaplan et al. BMC Health Services Research 2011, 11:22
http://www.biomedcentral.com/1472-6963/11/22
Page 5 of 9Surfactant use in moderately preterm infants with
RDS has the potential to be an ideal quality indicator if
it can be accurately measured and can be shown to be a
valid measure of quality. The best processes to use as
quality indicators are those care practices with strong
face validity and evidence linking them to improved
patient outcomes. Although there are very few evidence-
based therapies in neonatology, the efficacy of surfactant
therapy for RDS has been proven in multiple clinical
trials and a recent American Academy of Pediatrics
report states that surfactant should be given to intu-
bated infants with RDS regardless of exposure to
antenatal steroids or gestational age [10]
In an effort to establish the construct validity of sur-
factant use in infants 30 to 34 weeks’ gestation with
RDS, we have shown significant variation in rates of sur-
factant use across hospitals and that hospital surfactant
use was associated with variation in two of the most
commonly used measures of neonatal quality – volume
of admissions [16-18] and in-hospital mortality [17,19].
These findings are consistent with other examinations
of variation in care practices published in the literature.
For example, Horbar et al. documented variation in the
use of early surfactant among VLBW infants similar to
the variation we observed in larger preterm infants with
RDS [13]. Additionally, our finding that hospital rates of
surfactant use are associated with NICU volume of
admissions is consistent with previous reports demon-
strating a relationship between NICU volume of admis-
sions and improved mortality [16,17]. While these
results are encouraging, limitations in adequate mea-
surement of this quality metric including defining RDS
using administrative data, adequately adjusting for sever-
ity of illness, and accounting for care received prior to
transfer preclude us from establishing the validity of this
measure as a marker of neonatal quality of care. Addi-
tionally, this study did not attempt to demonstrate the
stability of the proposed quality measure over time.
Process measures require accurate identification of the
appropriate eligible patient population. Identifying
patients with RDS who are eligible for surfactant treat-
ment was particularly challenging using administrative
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Figure 2 Adjusted hospital odds of receiving surfactant relative
to reference hospital. This figure displays the hospital’s adjusted
odds ratio and associated 95% confidence interval (95% CI) of
receiving surfactant relative to reference hospital defined as having
the median adjusted rate of surfactant. After adjusting for patient
characteristics, five hospitals had significantly decreased odds and
four hospitals had significantly increased odds of giving surfactant,
compared to the median hospital. After Bonferoni correction for
multiple comparisons (p ≤ 0.05/16 = 0.003), 4 hospitals remained
significantly different than the reference hospital.
Table 2 Mean (O-E)/N for hospital surfactant use and
death
Hospital Surfactant use
Mean (95% CI)
p-value
Death
Mean (95% CI)
p-value
A 0.102 (0.082,0.122)
<0.001*
-0.130 (-0.166,-0.092)
<0.001*
B 0.196 (0.079,0.308)
0.010
0.011 (-0.004, 0.026)
0.219
C 0.131 (0.088,0.173)
<0.001*
0.003 (-0.006,0.012)
0.573
D 0.118 (0.065,0.172)
<0.001*
-0.004 (-0.014,0.006)
0.496
E 0.030 (-0.020,0.082)
0.312
0.00 (-0.012,0.011)
0.999
F 0.048 (0.026,0.071)
<0.001*
-0.017 (-0.021,-0.013)
<0.001*
G 0.043 (-0.031,0.114)
0.319
0.004 (-0.009,0.017)
0.534
H 0.027 (-0.086,0.137)
0.700
-0.005 (-0.024,0.015)
0.712
I 0.013 (-0.038,0.064)
0.659
-0.009 (-0.018,0.001)
0.129
J -0.035 (-0.087,0.016)
0.265
0.013 (0.004,0.022)
0.001*
K -0.065 (-0.113,-0.018)
0.020
-0.001 (-0.010,0.008)
0.845
L -0.117 (-0.177,-0.057)
0.001*
0.002 (-0.008,0.011)
0.771
M -0.164 (-0.240,-0.087)
<0.001*
0.006 (-0.010,0.022)
0.536
N -0.192 (-0.269,-0.111)
<0.001*
0.008 (-0.006,0.023)
0.472
O -0.298 (-0.337,-0.258)
<0.001*
0.033 (0.023,0.044)
<0.001*
P -0.350 (-0.436,-0.260)
<0.001*
0.027 (0.004,0.051)
0.041
*significant with p ≤ 0.05 after Bonferoni correction (p ≤ 0.05/16 = 0.003).
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infants requiring either NCPAP or MV in the first
48 hours of life. We believe this is a reasonable, practical
definition for a clinical condition whose definition has
varied even across clinical trials of surfactant therapy
[4-6]. The definition included both NCPAP and MV in
an effort to eliminate the effects of practice variation in
ventilatory management across hospitals because the
same infant, with the same severity of RDS, may be trea-
ted with NCPAP at one center and with MV at another
center. However, in doing so, the denominator of eligible
patients included some infants who could be successfully
managed on NCPAP and some with more mild RDS who
might not require surfactant treatment. The fact that
there was still significant variation among hospitals in the
use of surfactant when we used the ICD-9-CM diagnosis
code to identify infants with RDS and when we restricted
the population to only those infants requiring mechanical
ventilation suggests that true variation exists. However,
we acknowledge that there is a potential that systematic
differences in RDS severity across hospitals or more lib-
eral use of NCPAP in some centers could explain some
of the variation in surfactant rates seen across hospitals.
Future efforts to develop process measures in neonatol-
ogy should focus on care practices with a clear and well-
defined eligible patient population.
When the eligible patient population can be defined
appropriately, process measures are typically insensitive
to differences in case mix and severity of illness
[1,26-28]. However, outcomem e a s u r e so fq u a l i t ys u c h
as rates of in-hospital mortality (as used in this study
for testing construct validity) require adequate risk
adjustment to allow for fair and accurate comparisons
across hospitals [27,29-32]. Administrative data is the
most accessible comparative database for examining all
patients admitted to a hospital and therefore is an
important source of data for quality measurement [33].
However, administrative data sets often lack the richness
of clinical data sources and they do not typically include
physiologic measures of illness severity that can be used
for adjustment when making comparisons across hospi-
tals. While it is clear that physiologic measures of illness
severity can provide a more nuanced adjustment for dif-
ferences in case-mix related to illness severity, it is
unclear how much these measures add or subtract to
adjustments made using demographic and clinical vari-
ables as done commonly in other studies of variation in
care [16,20]. The variables used to adjust for differences
in case-mix when measuring surfactant use and in-hos-
pital mortality in this study included an available subset
of the demographic variables used in other studies. This
specific combination of variables may not have fully
accounted for differences in case-mix across hospitals
and for differences in severity of illness; therefore, some
of the variation we observed may be attributed to resi-
dual differences in case mix that were unaccounted for
by our adjustment model. Future efforts to use adminis-
trative data to measure neonatal quality will need to
first focus on developing valid risk adjustment models.
More refined neonatal risk adjustment models are cur-
rently under development for use with the PHIS data-
base (personal communication Matt Hall, CHCA).
Many neonatal quality measures are complicated by
the impact of patient transfers between hospitals, which
is a common occurrence in neonatal and perinatal care
[15]. For example, development of valid measures of
antenatal steroid use in eligible pregnant women is com-
plicated by the fact that steroids may be given in multi-
ple settings including outpatient clinics and referring
hospitals. Measuring surfactant use in infants with RDS
is similarly complicated. We do not have information on
whether infants received surfactant at an outside hospi-
tal prior to transfer. In both our initial analysis and in
sensitivity analyses, results were not affected by the day
of life when the infant was admitted, making it less
likely that receipt of surfactant at an outside hospital
influenced whether the infant was truly eligible for sur-
factant. However, it is possible that variation in surfac-
tant use across hospitals actually reflects differences the
care provided before transfer, instead of differences in
the quality of care provided by the accepting facility.
Future efforts to develop neonatal process measures of
quality will likely need to focus on aspects of care that
clearly occur at a single location or on developing
Figure 3 Association between hospital adjusted rates [(O-E)/N]
for surfactant use and mortality. This scatter plot displays hospital
adjusted rates [(O-E)/N] of surfactant use on the x-axis and hospital
adjusted rates of mortality [(O-E)/N] on the y-axis (note break in y-
axis). Although there was an outlier hospital, the overall trend in the
plot is consistent with an association between decreasing mortality
and increasing surfactant use (Kendall’s tau correlation coefficient of
0.37, p = 0.051).
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across multiple locations.
The hospitals that submit data to PHIS are mainly
academic children’s hospitals. Academic hospitals may
vary in their quality of care compared to non-academic
hospitals. In addition, we excluded centers with <40 eligi-
ble infants in the study period. These smaller NICUs may
be less likely to provide high quality care compared to
larger NICUs [16-18]. Therefore, additional efforts are
needed to generalize these results and to understand how
potential quality measures perform in non-academic or
smaller NICUs.
Conclusions
Our study was among the first to use administrative
data to examine a process measure reflecting neonatal
quality of care. While results were encouraging, chal-
lenges defining RDS using administrative data, ensuring
adequate risk adjustment, and accounting for care
received prior to transfer, did not allow us to draw defi-
nitive conclusions about the suitability of rates of surfac-
tant use in infants 30 to 34 weeks’ gestation with RDS
as a quality indicator. More studies aimed at developing
valid and reliable quality measures are needed in order
to provide neonatologists with tools to understand and
improve the care they provide.
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